Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
Agile Therapeutics (Nasdaq: AGRX) will report its first quarter 2021 financial results on May 4, 2021, after market close. A live conference call is scheduled for 4:30 p.m. EDT. Investors can join by dialing (866) 324-3683 for domestic calls or (509) 844-0959 internationally. The webcast will be available via their Investor Relations page. Agile aims to meet women's healthcare needs with its non-daily contraceptive, Twirla, utilizing proprietary Skinfusion technology.
- Scheduled reporting of first quarter financial results demonstrates transparency.
- Live conference call allows direct investor engagement.
- None.
Live Conference Call and Webcast at 4:30 p.m. EDT
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report first quarter 2021 financial results after the market close on Tuesday, May 4, 2021 as follows:
| Date | Tuesday, May 4, 2021 |
| Time | 4:30 p.m. EDT |
| Webcast (live and archived) | Events & Presentations |
| Dial-in numbers | (866) 324-3683 (U.S. toll-free) or (509) 844-0959 |
| Conference ID | 2334548 |
Investors interested in listening to the conference call may do so by dialing (866) 324-3683 for domestic callers or (509) 844-0959 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.
Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.
About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.
Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com
FAQ
When will Agile Therapeutics report its first quarter financial results?
What time is the Agile Therapeutics conference call?
How can I access the Agile Therapeutics webcast?
What is Twirla by Agile Therapeutics?
